SynAct Pharma AB (STO:SYNACT)
Sweden · Delayed Price · Currency is SEK 19.92
-0.53 (-2.59%)
Sep 2, 2026, 5:29 PM CET
SynAct Pharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 14.23 | 53.41 | 61.21 | 62.4 | 108.25 | 24 |
Cash & Short-Term Investments | 14.23 | 53.41 | 61.21 | 62.4 | 108.25 | 24 |
Cash Growth | -79.35% | -12.75% | -1.90% | -42.36% | 351.08% | 64.95% |
Other Receivables | 20.65 | 13.38 | 14.43 | 12.41 | 14.7 | 10.67 |
Receivables | 20.65 | 13.38 | 14.43 | 12.41 | 14.7 | 10.67 |
Prepaid Expenses | 5.29 | 4.56 | 18.37 | 0.26 | 17.29 | 0.25 |
Other Current Assets | -0 | -0 | -0 | -0 | -0 | 0 |
Total Current Assets | 40.17 | 71.35 | 94 | 75.06 | 140.23 | 34.92 |
Property, Plant & Equipment | 2.36 | 1.21 | 1.94 | 0.66 | 2.1 | 3.18 |
Long-Term Investments | - | 0.04 | 0.14 | 0.14 | 0.27 | 0.27 |
Long-Term Deferred Charges | 165.57 | 147.82 | 154.59 | 152.16 | - | - |
Other Long-Term Assets | 0.14 | 0.09 | 19.85 | 0 | - | - |
Total Assets | 208.24 | 220.52 | 270.52 | 228.02 | 142.6 | 38.37 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.66 | 9.49 | 17.35 | 9.67 | 4.72 | 4.25 |
Accrued Expenses | 4.57 | 11.14 | 10.09 | 9.82 | 4.91 | 7.89 |
Current Portion of Leases | 0.66 | 0.62 | 0.6 | 0.58 | 1 | 0.98 |
Other Current Liabilities | 0.17 | 0.28 | 0.42 | 4.88 | 4.38 | 2.27 |
Total Current Liabilities | 7.06 | 21.52 | 28.46 | 24.94 | 15.01 | 15.39 |
Long-Term Leases | 0.27 | 0.6 | 1.29 | 0.06 | 1.06 | 2.11 |
Long-Term Deferred Tax Liabilities | 18.08 | 17.5 | 18.3 | 18.02 | - | - |
Other Long-Term Liabilities | 11.16 | 10.61 | 8.3 | 8.82 | - | - |
Total Liabilities | 36.57 | 50.23 | 56.35 | 51.83 | 16.08 | 17.5 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 7.03 | 6.67 | 5.81 | 4.45 | 3.71 | 3.25 |
Additional Paid-In Capital | 878.94 | 835.34 | 762.8 | 646.57 | 394.84 | 193.6 |
Retained Earnings | -731.35 | -683.83 | -573 | -490.6 | -274.79 | -175.59 |
Comprehensive Income & Other | 17.05 | 12.11 | 18.56 | 15.77 | 2.77 | -0.4 |
Shareholders' Equity | 171.67 | 170.29 | 214.17 | 176.19 | 126.52 | 20.87 |
Total Liabilities & Equity | 208.24 | 220.52 | 270.52 | 228.02 | 142.6 | 38.37 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.93 | 1.21 | 1.88 | 0.64 | 2.06 | 3.09 |
Net Cash (Debt) | 13.3 | 52.2 | 59.33 | 61.76 | 106.18 | 20.91 |
Net Cash Growth | -80.25% | -12.02% | -3.94% | -41.84% | 407.85% | 43.72% |
Net Cash Per Share | 0.25 | 1.02 | 1.50 | 1.90 | 3.85 | 0.81 |
Filing Date Shares Outstanding | 56 | 53.33 | 49.01 | 35.57 | 31.82 | 26.01 |
Total Common Shares Outstanding | 56 | 53.33 | 46.49 | 35.57 | 29.65 | 26.01 |
Working Capital | 33.12 | 49.82 | 65.54 | 50.12 | 125.22 | 19.53 |
Book Value Per Share | 3.07 | 3.19 | 4.61 | 4.95 | 4.27 | 0.80 |
Tangible Book Value | 171.67 | 170.29 | 214.17 | 176.19 | 126.52 | 20.87 |
Tangible Book Value Per Share | 3.07 | 3.19 | 4.61 | 4.95 | 4.27 | 0.80 |